0RCQ.LSE NicOx S.A.

Healthcare Oil, Gas & Consumable Fuels London Exchange
0.3914 EUR
Close of Oct 3, 2026
0.2810 0.5655
Market cap
EUR 11.6M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2021.

Is 0RCQ.LSE undervalued?

Graham number

The Graham number of NicOx S.A. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NicOx S.A. fundamental analysis

No fundamental analysis for NicOx S.A. yet.

NicOx S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NicOx S.A.

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. It develops solutions to preserving vision and improve eye health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, an investigational ophthalmic treatme…

Full company profile